Abstract
No public abstract is available from the verified source records.
Leah Karliner, Deborah E Barnes, Giovanni B Frisoni, Nicolas Villain, Tammy L S Benzinger
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Lecanemab in early Alzheimer's Disease
10.1056/nejmoa2212948 · 2023
Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
10.1001/jama.2023.13239 · 2023
The AHEAD 3-45 study: design of a prevention trial for Alzheimer's disease
10.1002/alz.12748 · 2023
Donanemab in preclinical Alzheimer's disease: screening and baseline data from TRAILBLAZER-ALZ 3
10.1002/alz.70662 · 2025
Future Directions in Alzheimer's Disease and Related Disorders 1. Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders
10.1016/s1474-4422(26)00246-2 · 2026
Future Directions in Alzheimer's Disease and Related Disorders 2. Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
10.1016/s1474-4422(26)00285-1 · 2026
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
10.1002/alz.13859 · 2024
Alzheimer disease as a clinical–biological construct—an international working group recommendation
10.1001/jamaneurol.2024.3770 · 2024
Alzheimer's disease outlook: controversies and future directions
10.1016/s0140-6736(25)01389-3 · 2025
Unresolved referenced work
1968
Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study
10.1016/s1474-4422(25)00350-3 · 2025
Brain health services for the secondary prevention of cognitive impairment and dementia: opportunities, challenges, and the business case for existing and future facilities
10.1016/j.tjpad.2025.100098 · 2025
Dementia prevention in memory clinics: recommendations from the European task force for brain health services
10.1016/j.lanepe.2022.100576 · 2023
NIA–AA research framework: toward a biological definition of Alzheimer's disease
10.1016/j.jalz.2018.02.018 · 2018
Blood biomarkers to detect Alzheimer disease in primary care and secondary care
10.1001/jama.2024.13855 · 2024
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
10.1093/brain/awae346 · 2025
Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio
10.1001/jamaneurol.2026.1565 · 2026
Plasma MTBR–tau243 biomarker identifies tau tangle pathology in Alzheimer's disease
10.1038/s41591-025-03617-7 · 2025
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
10.1038/s41467-024-47286-5 · 2024
Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force
10.1001/jama.2023.24766 · 2024
Colorectal cancer screening: an updated modeling study for the US Preventive Services Task Force
10.1001/jama.2021.5746 · 2021
Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force
10.1001/jama.2018.10400 · 2018
Amyloid-beta pathology and cognitive performance in centenarians
10.1001/jamaneurol.2025.1734 · 2025
A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology
10.1038/s41591-025-04080-0 · 2026
Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial
10.1001/jama.2025.12923 · 2025
A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial
10.1016/s0140-6736(15)60461-5 · 2015
Effect of personalized risk-reduction strategies on cognition and dementia risk profile among older adults: the SMARRT randomized clinical trial
10.1001/jamainternmed.2023.6279 · 2024
2025 Alzheimer's disease facts and figures
10.1002/alz.70235 · 2025
Caregivers’ attitudes toward blood-based biomarker testing for Alzheimer's disease
10.1002/dad2.12549 · 2024
Research participant interest in learning results of biomarker tests for Alzheimer disease
10.1001/jamanetworkopen.2025.2919 · 2025
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
10.1016/s1474-4422(23)00447-7 · 2024
The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): executive summary of recommendations for specialty care
10.1002/alz.14337 · 2025
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
10.1016/s0140-6736(24)01296-0 · 2024
Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force
10.1001/jama.2022.12138 · 2022
Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis
10.1016/j.jacc.2007.06.063 · 2008
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
10.1056/nejmoa052306 · 2005
Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
10.1056/nejmoa1601277 · 2017
Trial of solanezumab in preclinical Alzheimer's disease
10.1056/nejmoa2305032 · 2023
Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals: longitudinal data from the A4 and LEARN studies
10.14283/jpad.2024.122 · 2024
Amyloid-related imaging abnormalities (ARIA) in clinical trials of gantenerumab in early Alzheimer disease
10.1001/jamaneurol.2024.3937 · 2025
External validation of the eRADAR risk score for detecting undiagnosed dementia in two real-world healthcare systems
10.1007/s11606-022-07736-6 · doi-reference
The electronic health record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR) brain health trial: protocol for an embedded, pragmatic clinical trial of a low-cost dementia detection algorithm
10.1016/j.cct.2023.107356 · doi-reference
Development and validation of eRADAR: a tool using EHR data to detect unrecognized dementia
10.1111/jgs.16182 · doi-reference
Passive digital markers for Alzheimer's disease and other related dementias: a systematic evidence review
10.1111/jgs.18426 · doi-reference
Development and validation of the American Heart Association's PREVENT equations
10.1161/circulationaha.123.067626 · doi-reference
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial
10.1002/alz.13803 · doi-reference
A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer's disease
10.1038/s41746-025-01583-5 · doi-reference
Primary care detection of Alzheimer's disease using a self-administered digital cognitive test and blood biomarkers
10.1038/s41591-025-03965-4 · doi-reference
Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial
10.1001/jamaneurol.2022.3392 · doi-reference
Advances in Alzheimer's disease research over the past two decades
10.1016/s1474-4422(22)00298-8 · doi-reference
An International Working Group viewpoint on stratifying risk and prevention of the clinical expression of Alzheimer's disease
10.1038/s43587-025-00977-0 · doi-reference
Lecanemab for early Alzheimer's disease: appropriate use recommendations from the French federation of memory clinics
10.1016/j.tjpad.2025.100094 · doi-reference
Person-specific contribution of neuropathologies to cognitive loss in old age
10.1002/ana.25123 · doi-reference
Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke
10.1056/nejmc2215148 · doi-reference
Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease
10.1038/s41467-023-43933-5 · doi-reference
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
10.1002/alz.70062 · doi-reference
Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials
10.1001/jamaneurol.2025.0065 · doi-reference